Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
|Videos|August 3, 2022
Dr. Shoag and Dr. Spratt share advice on adding SpaceOAR to your practice
Author(s)Urology Times staff
“Coordination between urology and radiation oncology, if urology is placing the device, is really critical,” says Jonathan E. Shoag, MD.
Advertisement
In this video, Jonathan E. Shoag, MD, and Daniel E. Spratt, MD, also discuss how the UH Seideman Cancer Center radiation oncology practice for prostate cancer has grown. Shoag is a urologist at University Hospitals and an assistant professor of urology at Case Western Reserve University School of Medicine, and Spratt is chair of Radiation Oncology at UH Cleveland Medical Center and a professor at Case Western Reserve University School of Medicine.
Advertisement
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5